CN118613264A - 与抗癌药物共同施用的包含酞嗪酮衍生物的药物组合物 - Google Patents

与抗癌药物共同施用的包含酞嗪酮衍生物的药物组合物 Download PDF

Info

Publication number
CN118613264A
CN118613264A CN202380018679.4A CN202380018679A CN118613264A CN 118613264 A CN118613264 A CN 118613264A CN 202380018679 A CN202380018679 A CN 202380018679A CN 118613264 A CN118613264 A CN 118613264A
Authority
CN
China
Prior art keywords
pharmaceutical composition
combination
administered
administration
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380018679.4A
Other languages
English (en)
Chinese (zh)
Inventor
李原植
河炅秀
鲁珢振
李铭宰
洪民主
崔盛渊
金桢恩
诸仁奎
俞英兰
林钟昰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edith Inc
Original Assignee
Edith Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edith Inc filed Critical Edith Inc
Publication of CN118613264A publication Critical patent/CN118613264A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380018679.4A 2022-01-25 2023-01-25 与抗癌药物共同施用的包含酞嗪酮衍生物的药物组合物 Pending CN118613264A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263302834P 2022-01-25 2022-01-25
US63/302,834 2022-01-25
PCT/IB2023/000030 WO2023144626A1 (en) 2022-01-25 2023-01-25 Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Publications (1)

Publication Number Publication Date
CN118613264A true CN118613264A (zh) 2024-09-06

Family

ID=87470837

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380018679.4A Pending CN118613264A (zh) 2022-01-25 2023-01-25 与抗癌药物共同施用的包含酞嗪酮衍生物的药物组合物

Country Status (14)

Country Link
US (1) US20250120970A1 (https=)
EP (1) EP4469051A4 (https=)
JP (1) JP2025505381A (https=)
KR (1) KR20240138069A (https=)
CN (1) CN118613264A (https=)
AU (1) AU2023210923A1 (https=)
CA (1) CA3249330A1 (https=)
CL (1) CL2024002218A1 (https=)
IL (1) IL314334A (https=)
JO (1) JOP20240162A1 (https=)
MA (1) MA66598A1 (https=)
MX (1) MX2024009168A (https=)
TW (1) TW202339753A (https=)
WO (1) WO2023144626A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
JP7626783B2 (ja) * 2020-04-21 2025-02-07 アイディーエンス カンパニー リミテッド フタラジノン誘導体及びその中間体を調製するプロセス
AU2020444056A1 (en) * 2020-04-21 2022-11-17 Idience Co., Ltd. Crystalline forms of phthalazinone compound

Also Published As

Publication number Publication date
MA66598A1 (fr) 2024-11-29
WO2023144626A1 (en) 2023-08-03
JOP20240162A1 (ar) 2024-07-23
EP4469051A4 (en) 2025-12-17
MX2024009168A (es) 2024-08-09
IL314334A (en) 2024-09-01
EP4469051A1 (en) 2024-12-04
US20250120970A1 (en) 2025-04-17
JP2025505381A (ja) 2025-02-26
TW202339753A (zh) 2023-10-16
KR20240138069A (ko) 2024-09-20
CL2024002218A1 (es) 2024-12-20
AU2023210923A1 (en) 2024-07-25
CA3249330A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
EP2034835B1 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
US12257237B2 (en) Tinostamustine for use in treating sarcoma
KR20160078987A (ko) 플리나불린 및 탁산의 조합에 의한 암 치료
CN108136207A (zh) 用于治疗癌症的联合疗法
BR112020010435A2 (pt) uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia
KR20200017487A (ko) 비알코올성 지방간염 치료를 위한 리코플리고진
EA035567B1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
US20220125792A1 (en) Use of composition containing cdk4/6 inhibitor in combination with anastrozole in preparation of medicament for treating tumor diseases
US20250120970A1 (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
HK40111558A (zh) 与抗癌药物共同施用的包含酞嗪酮衍生物的药物组合物
TW202029961A (zh) Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途
RU2784869C1 (ru) Чиаураниб для лечения мелкоклеточного рака легкого
CN110339195A (zh) 用于治疗胆管癌的喹啉衍生物
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
KR20250165438A (ko) Azd5305의 투여 레지먼
KR20250095627A (ko) 에스트로겐 수용체-매개 장애의 치료 방법
JP2026513665A (ja) Ａｚｄ５３０５の投与レジメント
TW202329970A (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
JP2019108385A (ja) がん治療
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111558

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination